{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:59:31Z","timestamp":1787788771358,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clinthera.2019.07.021","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T17:23:31Z","timestamp":1569432211000},"page":"1956-1971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma"],"prefix":"10.1016","volume":"41","author":[{"given":"Abhishek","family":"Kavati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryia","family":"Zhdanava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lecocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradd","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.07.021_bib1","series-title":"Asthma","year":"2018"},{"key":"10.1016\/j.clinthera.2019.07.021_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2500\/aap.2011.32.3518","article-title":"Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey","volume":"33","author":"Murphy","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2019.07.021_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/02770900903584019","article-title":"Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS)","volume":"47","author":"Stanford","year":"2010","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.clinthera.2019.07.021_bib4","series-title":"Xolair [prescribing Information]","year":"2016"},{"key":"10.1016\/j.clinthera.2019.07.021_bib5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2019.07.021_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2012.04.015","article-title":"Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma","volume":"109","author":"Lafeuille","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3109\/02770903.2011.618568","article-title":"Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases","volume":"48","author":"Lafeuille","year":"2011","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.clinthera.2019.07.021_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2019.07.021_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1752-699X.2011.00263.x","article-title":"Omalizumab in patients with severe asthma: the XCLUSIVE study","volume":"6","author":"Schumann","year":"2012","journal-title":"Clin Respir J"},{"key":"10.1016\/j.clinthera.2019.07.021_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2500\/aap.2018.39.4111","article-title":"Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma","volume":"39","author":"Pilon","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2019.07.021_bib15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201deffectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2019.07.021_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1067\/mai.2002.122635","article-title":"Significant variability in response to inhaled corticosteroids for persistent asthma","volume":"109","author":"Szefler","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib18","first-page":"76","article-title":"Phenotypes and endotypes of uncontrolled severe asthma: new treatments","volume":"23","author":"Campo","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib19","doi-asserted-by":"crossref","first-page":"133 e3","DOI":"10.1016\/j.anai.2016.12.010","article-title":"Asthma yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma","volume":"118","author":"Chipps","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib20","doi-asserted-by":"crossref","first-page":"524 e2","DOI":"10.1016\/j.anai.2017.09.056","article-title":"Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO","volume":"119","author":"Chipps","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.12.080","article-title":"Decreased asthma exacerbations and hospitalizations in PROSPERO (prospective Study to evaluate Predictors of clinical effectiveness in response to omalizumab)","volume":"139","author":"Chipps","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2016.04.001","article-title":"Assessing biomarkers in a real-world severe asthma study (ARIETTA)","volume":"115","author":"Buhl","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/JAA.S107982","article-title":"Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history","volume":"11","author":"Tabatabaian","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.clinthera.2019.07.021_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2019.07.021_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib29","first-page":"S94","article-title":"Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma\u2013summary report 2007","volume":"1205","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib30","series-title":"Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma: Full Report 2007","year":"2007"},{"key":"10.1016\/j.clinthera.2019.07.021_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2019.07.021_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2019.07.021_bib35","series-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma","year":"2018"},{"key":"10.1016\/j.clinthera.2019.07.021_bib36","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2019.07.021_bib37","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaci.2015.12.050","article-title":"Response to omalizumab therapy based on level of ige: a two year observational study (REALITY Study)","volume":"137","author":"Peters","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.07.021_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11882-017-0739-5","article-title":"Predictive biomarkers for asthma therapy","volume":"17","author":"Medrek","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2019.07.021_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2017.12.002","article-title":"Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab","volume":"134","author":"Suzukawa","year":"2018","journal-title":"Respir Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:47Z","timestamp":1758963047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0149291819303959"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}